LUCAR-E9D + LUCAR-E9K

LUCAR-E9D + LUCAR-E9K is a dual-targeted chimeric antigen receptor (CAR) T-cell therapy developed by Beijing GoBroad Hospital. This cell therapy product is engineered to target both CD19 and CD20 antigens, which are frequently expressed on the surface of B-cell malignancies. By simultaneously targeting two different antigens, the therapy aims to mitigate the risk of antigen escape, a common mechanism of resistance and relapse in single-target CAR-T therapies. It is currently being evaluated in a Phase I clinical trial for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, where it is administered following a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine.

Other names

CD19/CD20 dual-targeted CAR-T cellsLUCAR-E9D or LUCAR-E9K cells productLUCAR-E-9D or LUCAR-E9K cells productLUCAR-E 9D or LUCAR-E9K cells product